Advertisement

Periodic dosing regimens of atorvastatin and rosuvastatin for dyslipidemia: A systematic review and meta-analysis of randomized controlled trials

Published:January 04, 2017DOI:https://doi.org/10.1016/j.ejim.2016.12.014
      Statins constitute the major class of cholesterol-lowering drugs and 10–15% reported Statin induced myalgia [
      • Harper C.R.
      • Jacobson T.A.
      The broad spectrum of statin myopathy: from myalgia torhabdomyolysis.
      ]. Randomized controlled trials report that alternate day or once a week dosing of long acting statins (atorvastatin and rosuvastatin) minimized the incidence of myalgia. In the absence of a systematic review or a quantitative meta-analysis on the same, the present review was conducted.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Harper C.R.
        • Jacobson T.A.
        The broad spectrum of statin myopathy: from myalgia torhabdomyolysis.
        Curr. Opin. Lipidol. 2007; 18: 401-408
        • Aghasadeghi K.
        • Zare D.
        Efficacy of alternate day dosing of atorvastatin.
        J Chin Clin Med. 2007; 2: 547-551
        • Jafari M.
        • Ebrahimi R.
        • Ahmadi-Kashani M.
        • Balian H.
        • Bashir M.
        Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
        J. Cardiovasc. Pharmacol. Ther. 2003; 8: 123-126
        • Kumar B.
        • Agarwal P.K.
        • Pranjal P.
        • Meghwani M.K.
        Does alternate day dosing of statin suffice? A comparative study of O.D to A/D dosing of atorvastatin on hypercholesterolemia.
        Journal of Advance Researchers in Biol Sci. 2013; 5: 23-24
        • Ghia C.J.
        • Panda A.S.
        • Khobragade L.R.
        • Jha R.K.
        • Rambhad G.S.
        Alternate day versus once daily atorvastatin for primary prevention of CHD in naïve patients of dyslipidemia.
        J. Clin. Diagn. Res. 2014; 8: 27-31
        • Pramanik S.
        • Das A.K.
        • Chakrabarty M.
        • Bandyopadhyay S.K.
        • Ghosh M.
        • Dalai C.K.
        Efficacy of alternate-day versus everyday dosing of atorvastatin.
        Indian J. Pharm. 2012; 44: 362-365
        • Keleş T.
        • Akar Bayram N.
        • Kayhan T.
        • Canbay A.
        • Sahin D.
        • Durmaz T.
        • et al.
        The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
        Anadolu Kardiyol Derg. 2008; 8: 407-412
        • Matalka M.S.
        • Ravnan M.C.
        • Deedwania P.C.
        Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The alternate day versus daily dosing of atorvastatin study (ADDAS).
        Am. Heart J. 2002; 144: 674-677
        • Rifaie O.
        • Nammas W.
        Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study.
        Anadolu Kardiyol Derg. 2012; 12: 90-96
        • Pattanaik S.
        • Malhotra S.
        • Sharma Y.P.
        • Pandhi P.
        Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.
        J. Cardiovasc. Pharmacol. 2012; 59: 479-484
        • Malhotra K.
        • Aslam S.
        • Gupta P.D.
        A comparative evaluation of efficacy and safety of daily dosing versus alternate day dosing of rosuvastatin for dyslipidemic patients.
        Int J Med Dent Sci. 2013; 2: 111-120
        • Li J.J.
        • Yang P.
        • Liu J.
        • Jia Y.J.
        • Li Z.C.
        • Guo Y.L.
        • et al.
        Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers.
        Clin. Chim. Acta. 2012; 413: 139-142
        • Dulay D.
        • LalHaye S.A.
        • Lahey K.A.
        • Day A.G.
        Efficacy of alternate day versus daily dosing of rosuvastatin.
        Can J Cardiol. 2009; 25: e28-e31
        • Gumprecht J.
        • Gosho M.
        • Budinski D.
        • Hounslow N.
        Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidemia.
        Diabetes Obes. Metab. 2011; 13: 1047-1055
      1. United States Food and Drug Administration briefing document for the endocrinologic and metabolic drugs advisory committee 2013.
        (Available at) ([Accessed on 02 Feb 2016])